Chelator efficacy of deferasirox and deferoxamine determined by SQUID biosusceptometry.

被引：0
|
作者：
Grosse, Regine
Janssen, Gisela
Engelhardt, Rainer
Groeger, Marketa
Leismann, Oliver
Nielsen, Peter
Fischer, Roland
Janka, Gritta
机构：
[1] Univ Hamburg, Med Ctr, Interdisciplinary Clin Grp Metabolism, Hamburg, Germany
[2] Univ Dusseldorf, D-4000 Dusseldorf, Germany
[3] Novartis Pharma GmbH, Nurnberg, Germany
[4] Childrens Hosp & Res Ctr, HEDCO, Oakland, CA USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.1779.1779
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1779
引用
收藏
页码：505A / 505A
页数：1
相关论文
共 24 条
  • [1] Safety and Efficacy of Combined Chelation Therapy with Deferasirox and Deferoxamine in a Gerbil Model of Iron Overload
    Otto-Duessel, Maya
    Brewer, Casey
    Gonzalez, Ignacio
    Nick, Hanspeter
    Wood, John C.
    ACTA HAEMATOLOGICA, 2008, 120 (02) : 123 - 128
  • [2] EFFICACY AND SAFETY WITH DEFERASIROX (EXJADE®), A ONCE-DAILY ORAL CHELATOR IN THALASSEMIC ADULTS
    Vlachaki, V. E.
    Haralambidou, S. H.
    Perifanis, V. P.
    Spanos, G. S.
    Tsatra, I. T.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 463 - 463
  • [3] Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial
    Premawardhena, Anuja
    Perera, Chamodi
    Wijethilaka, Muditha Nayana
    Wanasinghe, Sakuni Keshani
    Rajakaruna, R. H. M. G.
    Samarasinghe, R. A. N. K. K.
    Williams, Senani
    Mettananda, Sachith
    BMJ OPEN, 2024, 14 (02):
  • [4] Optimizing Iron Chelator Treatment in Cardiac and Hepatic Siderosis: Efficacy of Divided Deferasirox (EXJADER) - Doses
    Grosse, Regine
    Jarisch, Andrea
    Yamamura, Jin
    Nielsen, Peter
    Fischer, Roland
    Janka, Gritta
    BLOOD, 2011, 118 (21) : 924 - 925
  • [5] The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis
    Ibrahim, Ashraf S.
    Gebremariam, Teclegiorgis
    French, Samuel W.
    Edwards, John E., Jr.
    Spellberg, Brad
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (02) : 289 - 292
  • [6] Deferoxamine, deferasirox, and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a randomised clinical trial
    Premawardhena, Anuja
    Wanasinghe, Sakuni
    Perera, Chamodi
    Wijethilaka, Muditha Nayana
    Rajakaruna, R. H. M. G.
    Samarasinghe, R. A. N. K. K.
    Williams, Senani
    Mettananda, Sachith
    LANCET REGIONAL HEALTH - SOUTHEAST ASIA, 2024, 30
  • [7] Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with β-thalassaemia: the ESCALATOR study
    Taher, Ali
    El-Beshlawy, Amal
    Elalfy, Mohsen S.
    Al Zir, Kusai
    Daar, Shahina
    Habr, Dany
    Kriemler-Krahn, Ulrike
    Hmissi, Abdel
    Al Jefri, Abdullah
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 82 (06) : 458 - 465
  • [8] Comparative Efficacy and Safety of Deferoxamine, Deferiprone and Deferasirox on Severe Thalassemia: A Meta-Analysis of 16 Randomized Controlled Trials
    Xia, Sujian
    Zhang, Weidong
    Huang, Liting
    Jiang, Hong
    PLOS ONE, 2013, 8 (12):
  • [9] Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments
    Takahiro Yamasaki
    Issei Saeki
    Isao Sakaida
    Hepatology International, 2014, 8 : 492 - 498
  • [10] Efficacy of iron chelator deferoxamine for hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma patients refractory to current treatments
    Yamasaki, Takahiro
    Saeki, Issei
    Sakaida, Isao
    HEPATOLOGY INTERNATIONAL, 2014, 8 : S492 - S498
123